G-Rex® for Virus-Specific T-Cell Therapy
From single-virus products to multivirus-specific T-cell banks, G-Rex® supports flexible, scalable manufacturing for autologous and allogeneic VST therapies.
The Value of Simplicity
Virus-specific T-cell manufacturing must accommodate different donors, viral targets, antigen-presentation strategies and product models.
G-Rex® provides one simple expansion platform that can support this diversity—from patient- or donor-specific products to scalable banks of multivirus-specific T cells.
G-Rex® eliminates the convoluted, manipulation-heavy workflows that have historically made VST manufacturing inaccessible
G-Rex® supports VST manufacturing across single-virus or multi-virus workflows, across diverse viral targets, and donor types.
G-Rex® has a well-documented history supporting the translation of virus specific T cell therapies from R&D to GMP.
The Gold Standard
For more than 15 years, the Center for Cell and Gene Therapy at Baylor College of Medicine, Houston Methodist Hospital and Texas Children’s Hospital has used G-Rex® to help advance virus-specific T-cell manufacturing—from rapidly generated donor-specific products to multivirus-specific T cells and third-party VST banks.
That adoption has extended to leading academic and clinical institutions, including Children’s National Hospital, Great Ormond Street Hospital, University College London, Hôpital Maisonneuve-Rosemont, Institut Cochin and Banc de Sang i Teixits. Across these institutions, G-Rex® has supported VSTs targeting CMV, EBV, adenovirus, BK virus, HHV-6 and other clinically important viruses.
G-Rex® has continued to support VST manufacturing as the field progressed from institution-specific clinical programs to third-party cell banks and a commercially approved allogeneic virus-specific T-cell therapy. Across academia and industry, G-Rex® has become the gold standard for virus-specific T-cell manufacturing.
A Typical Process
VST manufacturing begins with cells collected from a patient, stem-cell donor or healthy third-party donor. Antigen-specific T cells are stimulated or selected against one or more viral targets, expanded in G-Rex®, harvested and prepared for administration or cryopreserved for future use.
Recommended Products
The G-Rex® product family supports virus-specific T-cell manufacturing from small-scale process development through clinical production. Select the G-Rex® format that aligns with your starting cell number, required dose and manufacturing model.
G-Rex® Well Plates provide a simple, scalable platform for virus-specific T-cell (VST) manufacturing. PBMCs are stimulated with viral antigen peptide mixes (pepmixes) directly in the well plate's gas-permeable environment, enabling high-density expansion of antigen-specific CTLs with minimal manipulation. This reduces contamination risk and culture complexity compared to conventional 24-well plates.
G-Rex® bioreactors enable clinical-scale VST manufacturing by providing a high-volume, gas-permeable static culture environment that supports robust antigen-driven expansion of virus-specific T cells from PBMCs with minimal operator intervention. This reduces hands-on time, and a cGMP-compatible process transferable from bench to clinical scale.
Single-use, gamma-irradiated bags in 250 mL, 1 L, and 5 L formats. Port configurations and tubing materials are engineered for compatibility with closed-system G-Rex® bioreactors, so media addition and cell recovery stay inside a closed fluid path.
A complete GMP reagent ecosystem.Serum-free, xeno-free ExCellerate™ media paired with animal-free GMP IL-2, IL-7, IL-15, and IL-21 give a process consistent bioactivity, closed-system-ready formats, and a direct path from RUO to GMP without a reagent change.
Next Steps
Whether you are developing a new VST process, transitioning an existing workflow into G-Rex®, optimizing clinical manufacturing or scaling a third-party VST bank, our team can help you identify the right G-Rex® products and process strategy for your program.
Frequently Asked Questions
Published G-Rex® workflows include VSTs targeting CMV, EBV, adenovirus, BK virus, HHV-6, HIV and other clinically important viruses.
Yes. G-Rex® has been used to manufacture VST products targeting multiple viruses simultaneously, including three-, four- and five-virus-specific products.
Yes. Published workflows include patient-derived, stem-cell-donor-derived, healthy-donor-derived and third-party VST products.
Published workflows have used peripheral blood mononuclear cells, leukapheresis material and umbilical cord blood.
G-Rex® can support both the initial stimulation or pulsing of cells with viral peptide pools and their subsequent expansion. Initial stimulation is typically performed at a low working volume of approximately 1 mL/cm², followed by expansion at a larger working volume of approximately 10 mL/cm².
Yes. G-Rex® has supported the manufacture of cryopreserved third-party VST banks designed to provide partially HLA-matched products for multiple recipients.
Yes. Published workflows have incorporated genetic modification, including CAR and lentiviral engineering. Genetic modification can be performed directly in G-Rex® before continued expansion.
Have a different question? Connect with a G-Rex® Optimization Specialist.
Evidence & References
Explore the published evidence supporting the use of G-Rex across virus-specific T-cell research, development, and clinical manufacturing.
